14 active not recruiting, 13 recruiting, 10 completed, 4 not yet recruiting. 22 Phase 2, 17 Phase 1, 8 Phase 3, 1 Phase 4.
Follow belzutifan: new trials by email Literature Review of belzutifan trials Research Report on belzutifan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) Belzutifan - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 15 | 2026-10-13 | 2026-10-30 |
| Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis Belzutifan - Erythrocytosis, Pulmonary Hypertension | Phase 2 | Not yet recruiting | University of Utah | 16 | 2026-10-01 | 2026-10-26 |
| Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 150 | 2026-06-01 | 2026-05-20 |
| An Experimental Study of Belzutifan Impact on Catecholamine Metabolism Belzutifan - Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant | Phase 2 | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 12 | 2026-04-27 | 2026-07-02 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 758 | 2026-04-09 | 2026-10-29 |
| Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL) Belzutifan - Pheochromocytoma and Paraganglioma (PPGL) | Phase 4 | Recruiting | Longfei Liu，MD | 20 | 2026-04-01 | 2026-10-30 |
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2026-03-23 | 2026-10-21 |
| Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) Pembrolizumab, Belzutifan - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2025-12-19 | 2026-08-20 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 904 | 2025-11-26 | 2026-08-03 |
| Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) Belzutifan, Active Surveillance - Active Surveillance, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 78 | 2025-11-17 | 2026-05-22 |
| Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) Belzutifan, 89Zr-DFO-girentuximab, 89Zr-DFO-girentuximab PET - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Withdrawn | NYU Langone Health | 2025-09-15 | 2026-10-22 | |
| A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039) Metformin, Belzutifan - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2025-08-18 | 2025-10-15 |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) Belzutifan, Zanzalintinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-07-20 | 2026-10-27 |
| A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035) Belzutifan, Phenytoin - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2025-03-28 | 2025-06-13 |
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Belzutifan - Ovarian Cancer, Ovarian Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-12-20 | 2025-11-05 |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) Belzutifan, Fulvestrant, Everolimus - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 120 | 2024-11-27 | 2026-08-28 |
| MSD Belzutifan PAS Belzutifan - Von Hippel Lindau Disease | Withdrawn | Merck Sharp & Dohme LLC | 2024-06-30 | 2024-11-29 | ||
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma HC-7366, Belzutifan - Renal Cell Carcinoma | Phase 1 | Recruiting | HiberCell, Inc. | 80 | 2024-04-29 | 2026-10-02 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Renal Cell (24) · Kidney Neoplasms (8) · Parkinson Disease 4, Autosomal Dominant Lewy Body (5) · von Hippel-Lindau Disease (5) · Paraganglioma (4) · Pheochromocytoma (4) · Neoplasm Metastasis (3) · Neoplasms (3) · Adenoma, Islet Cell (1) · Breast Neoplasms (1) · Carcinoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Hemangioblastoma (1)
Merck Sharp & Dohme LLC (26) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Cambridge University Hospitals NHS Foundation Trust (1) · HiberCell, Inc. (1) · José Claudio Casali da Rocha (1) · Longfei Liu，MD (1) · NYU Langone Health (1) · Peter MacCallum Cancer Centre, Australia (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Utah (1) · Vall d'Hebron Institute of Oncology (1)
United States (33) · United Kingdom (15) · France (14) · South Korea (14) · Spain (14) · Australia (13) · Chile (13) · Canada (10) · Israel (10) · Netherlands (9) · Poland (9) · Brazil (8) · Czechia (7) · Denmark (7) · Germany (7)
Eric Jonasch, MD (2) · Josef T. Prchal, MD (1) · Ken Pienta, M.D (1) · Lewis Au, PhD, MBBS (1) · Longfei Liu, Doctor of Medicine (1) · Minas Economides, MD (1) · Panagiotis Konstantinopoulos, MD, PhD (1) · Ruth T Casey, MD PhD (1) · Toni K Choueiri, MD (1)
PMID 40712111, PMID 29257710, PMID 33888901, PMID 34818478, PMID 35397952, PMID 36064785, PMID 36752726, PMID 37011650, PMID 37062953, PMID 37882432, PMID 37940446, PMID 38008031, PMID 38926066, PMID 39167807, PMID 39233312, PMID 39284337, PMID 39756444, PMID 40112850, PMID 40228516, PMID 40796417, PMID 41115468, PMID 41124218, PMID 42070919, PMID 42384869, PMID 42586114
2023 (9), 2019 (3), 2025 (3), 2016 (1), 2018 (1), K12CA270377 (1), P50CA101942 (1)